ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03685448 |
|
Recruitment Status :
Recruiting
First Posted : September 26, 2018
Last Update Posted : February 16, 2022
|
Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Information provided by (Responsible Party):
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 30, 2022 |
| Estimated Study Completion Date : | April 30, 2024 |